Women taking combination HRT are at greater risk of breast cancerBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7231.333/a (Published 05 February 2000) Cite this as: BMJ 2000;320:333
- Deborah Josefson
- San Francisco
Women who use combination hormone replacement therapy (HRT) with oestrogen and progesterone face a greater breast cancer risk than those taking oestrogen alone, according to a new report (JAMA 2000; 283:485-91, 534-5).
The study, led by Dr Catherine Schairer, an epidemiologist at the US National Cancer Institute, analysed data on 46355 postmenopausal women. The researchers sought to determine whether commonly prescribed combination hormone replacement therapy placed women at increased risk of breast cancer compared with oestrogen alone.
Postmenopausal oestrogen replacement helps to mitigate menopausal symptoms such as hot flushes, vaginal dryness, and mood swings, and additionally has been found to protect against osteoporotic fractures, Alzheimer's disease, and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial